Rockwell Automation Approves $1 Billion for Common Stock Repurchase and Declares Quarterly Dividend on Common Stock
The Board of Directors of Rockwell Automation, Inc. (NYSE: ROK) today authorized the company to expend up to an additional $1 billion to repurchase shares of Rockwell Automation common stock. This is in addition to the authorization on June 4, 2014 to repurchase $1 billion worth of common stock, of which approximately $197 million was remaining as of April 5, 2016.
The Board also declared a quarterly dividend of 72.5 cents per share on its common stock, payable on June 10, 2016 to shareowners of record at the close of business on May 16, 2016.
“In the prior six fiscal years, we have returned more than $3.7 billion, or 84 percent of free cash flow, to shareowners through dividends and share repurchases,” said Keith D. Nosbusch, chairman and chief executive officer. “Our solid financial position and sustainable cash generation enable us to continue our strong track record of returning cash to shareowners while investing in the business and pursuing strategic acquisitions.”
Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and information, makes its customers more productive and the world more sustainable. Headquartered in Milwaukee, Wis., Rockwell Automation employs over 22,000 people serving customers in more than 80 countries.
Rockwell Automation, Inc.
VP Finance & Investor Relations
Darice L. Brown
External Communications Manager
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ADC-THERAPEUTICS11.12.2017 07:32 | pressemeddelelse
ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301
ADC-THERAPEUTICS11.12.2017 07:02 | pressemeddelelse
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-402
FL-GA-TELESIS11.12.2017 06:03 | pressemeddelelse
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske
ASTRAZENECA10.12.2017 23:47 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials
NJ-CELGENE/BLUEBIRD-BIO10.12.2017 16:32 | pressemeddelelse
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
GA-GILEAD-SCIENCES/KITE10.12.2017 16:32 | pressemeddelelse
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum